ClinSeq

ClinSeq ClinSeq is a clinical genomics research program initiated at the National Institutes of Health by investigators including Craig Venter-era contemporaries and leaders from the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute. It was developed in the context of post-Human Genome Project translational efforts, drawing on methods from projects such as the 1000 Genomes Project and initiatives like All of Us Research Program and UK Biobank to explore the integration of whole-genome sequencing into clinical practice. The program linked patient-centered research at institutions such as the Bethesda Naval Hospital and academic centers including Johns Hopkins Hospital and Mayo Clinic with policy dialogue at organizations like the American College of Medical Genetics and Genomics and World Health Organization.

Background

ClinSeq emerged amid debates at forums including the President's Council on Bioethics and workshops convened by the National Academies of Sciences, Engineering, and Medicine addressing translation of genomic discovery from efforts such as the Human Genome Project and the HapMap Project. Principal investigators coordinated with programs at the National Institutes of Health and collaborators at centers like Harvard Medical School, Stanford University School of Medicine, and Broad Institute to pilot clinical sequencing approaches first motivated by findings from studies such as the Framingham Heart Study and the Jackson Heart Study. The study drew on technological advances exemplified by platforms from Illumina, protocols refined at Wellcome Trust Sanger Institute, and clinical-genetic frameworks advanced by the American College of Medical Genetics and Genomics.

Study Design and Methods

ClinSeq employed prospective enrollment and deep phenotyping modeled after cohort frameworks like the Framingham Heart Study and the Nurses' Health Study, integrating whole-exome and whole-genome sequencing approaches pioneered in projects such as the 1000 Genomes Project and analytic pipelines developed at the Broad Institute and Genome Informatics groups. The protocol incorporated informed consent procedures influenced by guidance from the Belmont Report deliberations and regulatory oversight from the Food and Drug Administration and the Office for Human Research Protections. Data management harmonization used standards from the Global Alliance for Genomics and Health and metadata practices endorsed by the National Library of Medicine. Variant interpretation followed criteria informed by publications from the American College of Medical Genetics and Genomics and curated resources such as ClinVar and dbSNP.

Recruitment and Cohort Characteristics

Recruitment targeted volunteers through partnerships with healthcare centers including Johns Hopkins Hospital, community outreach modeled after initiatives by the American Heart Association, and referral networks connected to specialty centers like Cleveland Clinic. The cohort composition was characterized by age distributions and phenotypic spectra comparable to established cohorts such as the Framingham Heart Study and the Rotterdam Study, and included participants with family histories of conditions investigated in studies like the Cardiovascular Health Study and the Hereditary Breast and Ovarian Cancer research networks. Demographic and ancestry analyses referenced reference panels from the 1000 Genomes Project and population genetics work at the Wellcome Trust Sanger Institute and Harvard School of Public Health.

Key Findings and Contributions

ClinSeq contributed to identification of actionable variants in genes also studied in landmark publications from groups at the Broad Institute and the Scripps Research Institute, reporting penetrance estimates informed by comparisons to cohorts such as the UK Biobank and the Framingham Heart Study. Papers from the study influenced interpretation frameworks used by the American College of Medical Genetics and Genomics and variant curation practices at databases like ClinVar and LOVD. Findings intersected with clinical guidelines issued by societies including the American College of Cardiology and the American Heart Association regarding genomic risk for conditions assessed in trials such as PROMISE and ASCEND. Methodological contributions included pipelines aligned with tools from the Genome Analysis Toolkit consortium and data sharing practices resonant with the Global Alliance for Genomics and Health.

Ethical, Legal, and Social Implications

ClinSeq engaged with ethical debates raised in reports by the National Academies of Sciences, Engineering, and Medicine, legal analyses from scholars at Harvard Law School and Stanford Law School, and policy forums hosted by the Presidential Commission for the Study of Bioethical Issues. Issues addressed included return of incidental findings discussed in position statements from the American College of Medical Genetics and Genomics and privacy concerns debated in cases considered by the United States Supreme Court and regulatory guidance from the Office for Human Research Protections. Community engagement strategies paralleled models used by the All of Us Research Program and indigenous consultation practices involving entities like the National Congress of American Indians.

Impact and Subsequent Research

ClinSeq influenced subsequent translational efforts at initiatives such as the All of Us Research Program, the Geisinger MyCode Community Health Initiative, and international consortia including the 100,000 Genomes Project and the FinnGen study. It informed clinical implementation programs at centers like Mayo Clinic and Massachusetts General Hospital and methodological advances adopted by groups at the Broad Institute, Wellcome Trust Sanger Institute, and European Molecular Biology Laboratory. Ongoing scholarship connecting ClinSeq-style results to health policy cited reports from the National Academies of Sciences, Engineering, and Medicine, practice guidelines from the American College of Medical Genetics and Genomics, and reimbursement debates involving the Centers for Medicare & Medicaid Services.

Category:Human genetics studies